We are live on ! Find out more
BDTX icon

Black Diamond Therapeutics

111 hedge funds and large institutions have $71.3M invested in Black Diamond Therapeutics in 2026 Q3 according to their latest regulatory filings, with 25 funds opening new positions, 38 increasing their positions, 27 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

150% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 10

90% more capital inflows, than outflows

Capital inflows: $11.6M | Capital outflows: $6.12M

41% more repeat investments, than reductions

Existing positions increased: 38 | Existing positions reduced: 27

16% more funds holding

Funds holding: 96 → 111 (+15)

4.7% more ownership

Funds ownership: 61.17% → 65.87% (+4.7%)

Holders
111
Holders Change
+15
Holders Change %
+15.63%
% of All Funds
1.35%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
25
Increased
38
Reduced
27
Closed
10
Calls
$84​K
Puts
–
Net Calls
+$84​K
Net Calls Change
-⁠$532​K

BDTX Hedge Fund Activity: Q3 2026 in Review

111 of the 8,227 institutional investors tracked by Wall St. Rank reported a position in Black Diamond Therapeutics (BDTX) for Q3 2026, worth a combined $71.3M — up 9.9% from $64.9M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new BDTX positions and 10 closed out — a net gain of 15 holders — while 38 added to existing stakes and 27 trimmed.

The largest buyer was Bank of America, adding an estimated $3.2M. The largest seller was Balyasny Asset Management, cutting an estimated $891K.

  • 111 institutional investors held Black Diamond Therapeutics (BDTX) as of Q3 2026, up from 96 in Q2 2026.
  • Funds reported $71.3M of Black Diamond Therapeutics stock for Q3 2026, up 9.9% quarter-over-quarter.
  • 25 funds opened new Black Diamond Therapeutics positions in Q3 2026 and 10 closed out, a net change of +15 holders.
  • The largest Black Diamond Therapeutics buyer in Q3 2026 was Bank of America, an estimated $3.2M added.
  • The largest Black Diamond Therapeutics seller in Q3 2026 was Balyasny Asset Management, an estimated $891K sold.

Based on aggregated 13F filings for Q3 2026.